| Followers | 200 |
| Posts | 25597 |
| Boards Moderated | 0 |
| Alias Born | 04/03/2010 |
Thursday, December 31, 2020 8:19:37 AM
Exactly. Thanks. I also think we know it’s unlikely, and we know the endpoints have been changed. But we also know the FDA maintains maximum flexibility on these matters.
Almost nothing can be certain until we know and the Company, I believe will do their best to inform us as quickly as they can, once they have an adequate analysis by their panel of experts and they have carefully crafted their plan for a factually accurate and complete reveal.
No 4 day rule applies, but clearly they are still subject to the normal fraud protections for investors, broadly speaking. It’s a complex dance. Early disclosure is the best policy, but it is not always possible to be accurate without careful review if the data and the ultimate statement by the relevant, important stakeholders and experts.
Almost nothing can be certain until we know and the Company, I believe will do their best to inform us as quickly as they can, once they have an adequate analysis by their panel of experts and they have carefully crafted their plan for a factually accurate and complete reveal.
No 4 day rule applies, but clearly they are still subject to the normal fraud protections for investors, broadly speaking. It’s a complex dance. Early disclosure is the best policy, but it is not always possible to be accurate without careful review if the data and the ultimate statement by the relevant, important stakeholders and experts.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
